Stomach Cancer Treatment in India
Comprehensive gastric cancer treatment in India — laparoscopic gastrectomy, FLOT chemotherapy, HER2-targeted therapy, and immunotherapy. Expert GI oncologists, costs 70% lower.
Estimated cost: $4,500 – $9,000 · Average stay: 8–12 days
Gastric cancer — cancer of the stomach — is the fifth most commonly diagnosed cancer globally and the fourth leading cause of cancer-related death, with approximately 1.1 million new cases annually. The prognosis is strongly stage-dependent: early-stage gastric cancer detected at stage I carries a 5-year survival exceeding 70%, while advanced stage IV disease remains challenging with median survival of 12–18 months even with modern systemic therapy.
The treatment of gastric cancer has evolved considerably. Perioperative chemotherapy — given both before and after surgery — has become the standard of care in Western guidelines (FLOT protocol: docetaxel, oxaliplatin, leucovorin, 5-FU), improving curative resection rates and survival compared to surgery alone. Minimally invasive gastrectomy (laparoscopic or robotic) is preferred at high-volume centers, offering equivalent oncologic outcomes with faster recovery.
Systemic therapy has also advanced: trastuzumab (Herceptin) benefits HER2-positive gastric cancer patients in the first-line metastatic setting. Immune checkpoint inhibitors (pembrolizumab, nivolumab) have demonstrated meaningful survival benefits in combination with chemotherapy for advanced gastric cancer.
India's top gastric cancer centers operate dedicated upper GI oncology units, combining experienced hepatobiliary/GI surgeons, medical oncologists, and gastroenterologists in cohesive multidisciplinary teams. Treatment costs are 70–80% below equivalent care in the USA or Japan.
Types and Staging of Gastric Cancer
Gastric adenocarcinoma accounts for over 95% of stomach cancers. Within adenocarcinoma, two major subtypes exist:
Intestinal type: more common in older patients, associated with H. pylori infection and dietary factors. Tends to form polypoid or ulcerative lesions, grows along the stomach wall, and has a somewhat better prognosis.
Diffuse type: characterized by poorly cohesive cells infiltrating the stomach wall without forming discrete masses. Includes signet ring cell carcinoma. More aggressive, higher risk of peritoneal spread, and more common in younger patients.
Lauren classification divides gastric cancer into these two types plus a mixed subtype.
AJCC/TNM staging:
- Stage I: Tumor confined to the stomach mucosa/submucosa, minimal lymph node involvement. Surgery alone can be curative.
- Stage II: Deeper muscular invasion with regional node involvement. Perioperative chemotherapy + surgery is standard.
- Stage III: Extensive local invasion with significant lymph node burden. Perioperative chemotherapy is critical.
- Stage IV: Distant metastases (liver, peritoneum, ovaries). Palliative systemic chemotherapy is the primary treatment.
Who Is a Candidate for Gastric Cancer Surgery?
Surgery with curative intent is offered to patients with stage I–III gastric cancer who are medically fit and whose tumor is confined to the stomach and regional lymph nodes without distant metastases.
Perioperative chemotherapy (3 cycles FLOT before surgery + 4 cycles after) is now the standard approach for stage II–III resectable gastric cancer in most international guidelines. Surgery alone is appropriate for early stage I disease detected by endoscopic staging.
Subtotal gastrectomy is performed when the tumor is in the distal stomach (antrum or pylorus), preserving part of the stomach. Total gastrectomy is required for proximal or diffuse tumors. Extended D2 lymphadenectomy — removing the second echelon of perigastric lymph nodes — is the required surgical quality standard at expert centers.
Stage IV gastric cancer is generally not surgically curable, but palliative resection or bypass is occasionally considered to relieve obstruction or bleeding. Systemic chemotherapy with fluoropyrimidine + platinum ± trastuzumab (for HER2-positive tumors) ± nivolumab (for high PD-L1 expression) is the primary treatment.
Gastric Cancer Surgery and Chemotherapy
Perioperative chemotherapy plus gastrectomy is the evidence-based approach for stages II–III resectable gastric cancer. Three cycles of FLOT (docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m², and 5-FU 2600 mg/m² continuous infusion) are given before surgery (every 2 weeks), followed by the gastrectomy, followed by 4 more cycles of FLOT post-operatively.
Laparoscopic D2 gastrectomy has become the preferred surgical approach at high-volume centers with experienced GI oncologic surgeons. Compared to open gastrectomy, it offers equivalent 3-year disease-free survival, less blood loss, faster return of bowel function, shorter hospital stay, and reduced wound complications. Robotic gastrectomy is offered at select centers.
For HER2-positive advanced gastric cancer (approximately 20% of cases): trastuzumab is added to first-line chemotherapy (XELOX or FOLFOX). Ramucirumab, an anti-VEGFR2 antibody, is used in second-line therapy. Pembrolizumab has demonstrated improved survival in patients with high PD-L1 CPS scores.
Procedure Steps
- Diagnosis and staging: upper endoscopy with biopsy, CT chest/abdomen/pelvis, endoscopic ultrasound for T and N staging.
- Molecular testing: HER2 immunohistochemistry/FISH and PD-L1 CPS scoring for treatment selection.
- Multidisciplinary tumor board case review: gastric cancer specific team determines resectability and treatment sequence.
- Neoadjuvant chemotherapy (stage II–III): 3 cycles FLOT given over 6 weeks; repeat CT to confirm response.
- Laparoscopic or robotic D2 gastrectomy: subtotal or total depending on tumor location; meticulous lymphadenectomy.
- Pathological assessment: final staging, R0 margin status, and nodal yield (minimum 16 nodes required).
- Adjuvant chemotherapy: 4 cycles FLOT starting 4–6 weeks after surgery.
- Surveillance: CT every 6 months; CEA, CA 19-9 every 3 months; upper endoscopy at 1 and 3 years.
Gastric Cancer Treatment Approaches
Laparoscopic D2 Gastrectomy
Minimally invasive removal of the stomach (subtotal or total) with extended D2 regional lymphadenectomy. The recommended surgical standard at high-volume GI oncology centers. Equivalent oncologic outcomes to open surgery with faster recovery, less blood loss, and shorter hospitalization.
Cost: $4,500 – $9,000
FLOT Perioperative Chemotherapy
Docetaxel + oxaliplatin + leucovorin + 5-FU given as 3 pre-surgical and 4 post-surgical cycles. Improves R0 resection rates and significantly increases 5-year survival compared to epirubicin-based regimens. The current global standard for resectable stage II–III gastric cancer.
Cost: $800 – $2,000 per cycle
Trastuzumab + Chemotherapy (HER2+)
Trastuzumab (Herceptin) added to XELOX or FOLFOX chemotherapy for HER2-overexpressing advanced gastric cancer. Improves median overall survival from 11 to 14 months in the ToGA trial. Available as a biosimilar in India at significantly reduced cost.
Cost: $500 – $2,000 per cycle (biosimilar)
Pembrolizumab + Chemotherapy
PD-1 checkpoint inhibitor combined with platinum-based chemotherapy for first-line treatment of advanced gastric cancer with high PD-L1 CPS (≥5). The KEYNOTE-590 and KEYNOTE-811 trials demonstrated improved survival with pembrolizumab addition.
Cost: $1,500 – $4,000 per cycle
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $4,500 – $9,000 — Save 70–80%
UAE — $8,000 – $15,000 — Save 55–65%
USA / Japan — $25,000 – $80,000+ — Baseline
Gastric cancer surgery with perioperative chemotherapy in India costs approximately $8,000–$18,000 total (surgery + full chemotherapy course) — compared to $80,000–$200,000+ in the United States. HER2-positive patients benefit from trastuzumab biosimilars available at 80–90% less than branded Herceptin. Expert care does not require a premium price tag.
Recovery & Follow-up
Hospital stay after laparoscopic gastrectomy is typically 7–10 days. A nasogastric tube is removed by day 2–3; liquid diet begins day 3–4; soft foods by week 2–3. Full dietary adaptation to the smaller stomach takes 3–6 months. Vitamin B12 and iron supplementation are required long-term after total gastrectomy. Adjuvant chemotherapy begins 4–6 weeks after surgery.
Recovery Tips
- Eat small, frequent meals (6–8 per day) after gastrectomy — the stomach's capacity is significantly reduced.
- Avoid concentrated sweet foods and drinks to prevent dumping syndrome (rapid stomach emptying causing nausea, flushing, diarrhea).
- Take vitamin B12 injections monthly after total gastrectomy — intrinsic factor secretion is eliminated.
- Iron and folate supplementation is essential to prevent anemia.
- Attend all follow-up appointments — gastric cancer has a significant risk of recurrence in the first 2–3 years.
Risks & Complications
Gastrectomy risks include anastomotic leak (1–5%), duodenal stump blow-out, wound infection, and post-gastrectomy syndromes (dumping syndrome, bile reflux). FLOT chemotherapy risks include neutropenia, neuropathy, mucositis, and diarrhea. Trastuzumab carries a small risk of cardiac dysfunction — baseline echocardiogram is performed. All risks are discussed comprehensively during the pre-operative consultation.
Why GAF Healthcare
Gaf Healthcare connects international gastric cancer patients with India's highest-volume GI oncology centers, where experienced surgeons perform over 200 gastrectomies annually. We arrange rapid multidisciplinary review, including HER2 testing results within 48 hours, and coordinate perioperative chemotherapy scheduling around international travel to minimize time away from home.
Frequently Asked Questions
What is the survival rate for gastric cancer treated in India?
Five-year survival rates: Stage I — 65–85%, Stage II — 40–65%, Stage III — 20–40%, Stage IV — 5–10%. India's top GI oncology centers achieve outcomes equivalent to leading Japanese and South Korean centers, which have the world's highest gastric cancer volume and expertise.
What is the FLOT protocol and why is it better than ECF?
FLOT (docetaxel + oxaliplatin + leucovorin + 5-FU) is the current first-line perioperative chemotherapy for resectable gastric cancer. The FLOT4 trial demonstrated superior 5-year overall survival (45% vs 36%) and R0 resection rates compared to older ECF/ECX regimens. FLOT is the recommended protocol at India's leading cancer centers.
Do I need surgery if I have stage IV gastric cancer?
In stage IV gastric cancer, surgery is generally not curative. The primary treatment is systemic chemotherapy. However, surgical resection of the primary tumor may be considered for relief of obstruction or bleeding. Selected patients with very limited peritoneal or liver metastases may occasionally be offered surgery at specialized centers.
Is HER2 testing done for gastric cancer?
Yes. All advanced gastric cancer patients should have HER2 testing. Approximately 15–20% of gastric cancers overexpress HER2, and these patients benefit from trastuzumab added to first-line chemotherapy. India's top centers perform HER2 immunohistochemistry and FISH testing with rapid turnaround.
How long does gastric cancer treatment take?
Perioperative treatment takes approximately 8 months total: 6 weeks of neoadjuvant chemotherapy (3 FLOT cycles), surgery (10–14 days including hospital stay), then 8 weeks of adjuvant chemotherapy recovery, followed by 4 more FLOT cycles over 8 weeks. Surgery itself takes 3–5 hours.